The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model
Abstract
Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate essential genes. Because complete ADNP deficiency is embryonic lethal, the outcome of partial ADNP deficiency was examined. ADNP(+/-) mice exhibited cognitive deficits, significant increases in phosphorylated tau, tangle-like structures, and neurodegeneration compared with ADNP(+/+) mice. Increased tau hyperphosphorylation is known to cause memory impairments in neurodegenerative diseases associated with tauopathies, including the most prevalent Alzheimer's disease. The current results suggest that ADNP is an essential protein for brain function and plays a role in normal cognitive performance. ADNP-deficient mice offer an ideal paradigm for evaluation of cognitive enhancers. NAP (NAPVSIPQ) is a peptide derived from ADNP that interacts with microtubules and provides potent neuroprotection. NAP treatment partially ameliorated cognitive deficits and reduced tau hyperphosphorylation in the ADNP(+/-) mice. NAP is currently in phase II clinical trials assessing effects on mild cognitive impairment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“while ADNP+/- mice show tauopathy, neuronal cell death and abnormalities in social behaviour and cognitive functioning18,34.”
From A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP (2014) · cites this paper as [18]
In the citing paper
“Of the other genes reported as differentially expressed in Adnp-/-23 and Adnp+/-18 mice (down: CCNC, TMPO, PLAGL2; up: ABCF3), only PLAGL2 was found to be differentially regulated in our patients (Supplementary Fig. 3e).”
From A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP (2014) · cites this paper as [18]
Citations
Cites
Grundman, M. (2004) · Archives of Neurology · doi:10.1001/archneur.61.1.59 · Cited by 972
Roles of Pax-genes in developing and adult brain as suggested by expression patterns
Stoykova, A., & Gruss, P. (1994) · Journal of Neuroscience · doi:10.1523/jneurosci.14-03-01395.1994 · Cited by 577
Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration
Wang, J., Grundke, I., & Iqbal, K. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05226.x · Cited by 569
Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo
Fulga, T. A., Elson-Schwab, I., Khurana, V., Steinhilb, M. L., Spires, T. L., Hyman, B. T., & Feany, M. B. (2007) · Nature Cell Biology · doi:10.1038/ncb1528 · Cited by 452
Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses
Mandelkow�, E. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.04.007 · Cited by 412
Bassan, M., Zamostiano, R., Davidson, A., Pinhasov, A., Giladi, E., Perl, O., Bassan, H., Blat, C., Gibney, G., Glazner, G. W., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721283.x · Cited by 394
Self-citationThe Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation
Plattner, F., Angelo, M., & Giese, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603469200 · Cited by 340
New roles for astrocytes (stars at last)
Ransom, B. R., Behar, T. N., & Nedergaard, M. (2003) · Trends in Neurosciences · doi:10.1016/j.tins.2003.08.006 · Cited by 335
Cloning and Characterization of the Human Activity-dependent Neuroprotective Protein
Zamostiano, R., Pinhasov, A., Gelber, E., Steingart, R. A., Seroussi, E., Giladi, E., Bassan, M., Wollman, Y., Eyre, H. J., Mulley, J. C., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007416200 · Cited by 251
Self-citationActivity-dependent neuroprotective protein: a novel gene essential for brain formation
Pinhasov, A., Mandel, S., Torchinsky, A., Giladi, E., Pittel, Z., Goldsweig, A. M., Servoss, S. J., Brenneman, D. E., & Gozes, I. (2003) · Developmental Brain Research · doi:10.1016/s0165-3806(03)00162-7 · Cited by 239
Self-citation
Cited by
Sorted by citations
Items 101–200 of 219
Gozes, I., Ivashko‐Pachima, Y., & Sayas, C. L. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00151 · Cited by 28
“Parallel studies identified reduced axonal transport (Amram et al., 2016), increased tau hyperphosphorylation and tau depositions as a consequence of Adnp haploinsufficiency (Vulih-Shultzman et al., 2007).”
BackgroundSelf-citationLogroscino, G., Imbimbo, B. P., Lozupone, M., Sardone, R., Capozzo, R., Battista, P., Zecca, C., Dibello, V., Giannelli, G., Bellomo, A., et al. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1598377 · Cited by 30
Duggal, P., & Mehan, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190125 · Cited by 28
Ivashko‐Pachima, Y., & Gozes, I. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.07.008 · Cited by 25
Self-citationGozes, I., Shapira, G., Lobyntseva, A., & Shomron, N. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02618-9 · Cited by 26
Self-citationProtein and Peptide in Drug Targeting and its Therapeutic Approach
Keservani, R. K., Sharma, A. K., & Jarouliya, U. (2015) · Ars Pharmaceutica (Internet) · doi:10.4321/s2340-98942015000300006 · Cited by 26
Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies
Badiola, N., Suárez‐Calvet, M., & Lleó, A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710793237403 · Cited by 26
“Mice lacking ADNP showed an increase in tau phosphorylation and neurodegeneration, and these features were reverted when NAP was administrated to mice [211].”
BackgroundDevelopmental Phenotype of the Rare Case of DJ Caused by a Unique ADNP Gene De Novo Mutation
Levine, J., Cohen, D., Herman, C., Verloès, A., Guinchat, V., Diaz, L., Cravero, C., Mandel, A., & Gozes, I. (2019) · Journal of Molecular Neuroscience · doi:10.1007/s12031-019-01333-9 · Cited by 24
Self-citationTownsend, J. A., Braz, C. U., Taylor, T., & Khatib, H. (2022) · Current Zoology · doi:10.1093/eep/dvac029 · Cited by 24
“ADNP2’s homolog, ADNP, is essential for brain formation and function [76, 77], neurite outgrowth [78], and glial-derived neuroprotection, and a complete deficiency is considered embryonic lethal [79].”
BackgroundZemlyak, I., Manley, N. C., Vulih, I., Cutler, A. B., Graber, K., Sapolsky, R. M., & Gozes, I. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06415.x · Cited by 24
“Complete knockout of the NAP parent protein, ADNP, resulted in embryonic lethality at the time of neural tube closure and brain formation (Pinhasov et al. 2003).”
BackgroundInfluentialSelf-citationActivity-Dependent Neuroprotective Protein Modulates Its Own Gene Expression
Aboonq, M. S., Vasiliou, S. A., Haddley, K., Quinn, J. P., & Bubb, V. J. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9562-y · Cited by 23
“Furthermore, ADNP has been postulated to have a protective role against cognitive deficits and neurodegenerative diseases (Vulih-Shultzman et al. 2007), and ADNP may be involved in neuroprotective mechanisms in foetal alcohol syndrome in a self-sustaining status epilepticus (SSSE) model and in schizophrenia (Poggi et…”
BackgroundKolevzon, A. L., Levy, T., Barkley, S. B., Bedrosian‐Sermone, S., Davis, M. M., Foss‐Feig, J. H., Halpern, D. B., Keller, K., Kostić, A., Layton, C., et al. (2022) · Human Genetics and Genomics Advances · doi:10.1016/j.xhgg.2022.100138 · Cited by 24
“This is an open access article under the CC BY-NC-ND reduced dendritic spine density, spatial learning deficits, memory impairment, muscle weakness, and communication problems.(10,11) Advances inunderstanding the pathophysiologicalmechanisms of ADNP syndromehave created important opportunities for developing novel and…”
Kapitansky, O., Sragovich, S., Jaljuli, I., Hadar, A., Giladi, E., & Gozes, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186715 · Cited by 21
“The genes/proteins presented a crucial network biological process role for proper muscle function as also previously revealed by mouse and human RNA-seq [12,14], as well as ff etrix arra [16] (Table S1).”
BackgroundMethodSelf-citationTargeting Tau to Treat Clinical Features of Huntington's Disease
Masnata, M., Salem, S., Jacquet, A. D. R., Anwer, M., & Cicchetti, F. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.580732 · Cited by 25
“In a Tg schizophrenia mouse model (activitydependent neuroprotective protein (ADNP) Tg mice), intranasal administration of NAP decreased brain levels of ptau and improved cognition (236).”
BackgroundBeyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease
Ruthirakuhan, M. T., Herrmann, N., Suridjan, I., Abraham, E. H., Farber, I., & Lanctôt, K. L. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258060 · Cited by 21
“In preclinical studies with transgenic mouse models, ADNP reduced tau hyperphosphorylation and ameliorated cognitive deficits [86,87].”
BackgroundZiv, Y., Rahamim, N., Lezmy, N., Even‐Chen, O., Shaham, O., Malishkevich, A., Giladi, E., Elkon, R., Gozes, I., & Barak, S. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0132-7 · Cited by 22
“To this end, we used Adnp haploinsufficient mice (Adnp [14, 19, 25]), as ADNP is crucial for brain formation and knockout mice die during embryonic development [13].”
BackgroundMethodResultInfluentialSelf-citationSingle Cell ADNP Predictive of Human Muscle Disorders: Mouse Knockdown Results in Muscle Wasting
Kapitansky, O., Karmon, G., Sragovich, S., Hadar, A., Shahoha, M., Jaljuli, I., Bikovski, L., Giladi, E., Pálovics, R., Iram, T., et al. (2020) · Cells · doi:10.3390/cells9102320 · Cited by 20
“Two mouse models were used: (1) The Adnp+/− mice, on a mixed C57BL and 129/Sv background [4,21,28,46,47], outbred with an ICR mouse line for continuous breeding [21,25].”
BackgroundMethodSelf-citationGozes, I. (2010) · Peptides · doi:10.1016/j.peptides.2010.10.030 · Cited by 21
Self-citationCiesler, J., & Sari, Y. (2013) · Open Journal of Neuroscience · doi:10.13055/ojns_3_1_2.130408 · Cited by 21
“In addition, studies have found that treatment with NAP in ADNP knockdown mice resulted in enhanced cognition and improved associated deficiencies [48].”
BackgroundShapira, G., Karmon, G., Hacohen-Kleiman, G., Ganaiem, M., Shazman, S., Theotokis, P., Grigoriadis, N., Shomron, N., & Gozes, I. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02879-w · Cited by 19
Self-citationJouroukhin, Y., Ostritsky, R., & Gozes, I. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9882-6 · Cited by 20
Self-citationDisease-modifying therapies for tauopathies: agents in the pipeline
Panza, F., Imbimbo, B. P., Lozupone, M., Greco, A., Seripa, D., Logroscino, G., Daniele, A., & Colosimo, C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1606715 · Cited by 20
“mice, davunetide has been shown to decrease tau phosphorylation [111].”
BackgroundGozes, I. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23808 · Cited by 20
“Overall, ADNP is essential for embryogenesis (brain formation; Pinhasov et al., 2003), provides neuroprotection (Steingart et al., 2006), and protects cognition (Vulih-Shultzman et al., 2007) and social behavior/memory (Amram et al., 2016).”
BackgroundInfluentialSelf-citationWang, H. V., Forestier, S., & Corces, V. G. (2021) · Biology of Reproduction · doi:10.1093/biolre/ioab097 · Cited by 19
The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP
Gozes, I. (2015) · Biological Chemistry · doi:10.1515/hsz-2015-0152 · Cited by 19
Self-citationD’Incal, C. P., Dijck, A. V., Ibrahim, J., Man, K. D., Bastini, L., Konings, A., Elinck, E., Theys, C., Gozes, I., Marušić, Z., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01743-w · Cited by 18
“RNA sequencing data of the ADNP brain autopsy was subsequently analyzed for the enrichment of specialized pathways associated with autophagy [53, 54], neuroprotection [55, 56], and mitochondrial biogenesis [57] with a costomized gene toolbox [34].”
BackgroundMethodSelf-citationGozes, I., & Ivashko‐Pachima, Y. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00205 · Cited by 18
“…against tauopathy in vitro (Gozes and Divinski, 2004; Shiryaev et al., 2011; Idan-Feldman et al., 2012) and in vivo (Matsuoka et al., 2007, 2008; Vulih-Shultzman et al., 2007; Shiryaev et al., 2009; Jouroukhin et al., 2013; Magen et al., 2014), in part, by enlisting tau back to the microtubules…”
BackgroundSelf-citationNeuroprotective Protein and Carboxypeptidase E
Koshimizu, H., Senatorov, V. V., Loh, Y. P., & Gozes, I. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9164-5 · Cited by 18
Self-citationSomatic Mutations and Alzheimer’s Disease
Downey, J., Lam, J. C. K., Li, V. O. K., & Gozes, I. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220643 · Cited by 18
Self-citationAvian models for brain mechanisms underlying altered social behavior in autism
Csillag, A., Ádám, Á., & Zachár, G. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.1032046 · Cited by 18
D-SAL and NAP: Two Peptides Sharing a SIP Domain
Gozes, I., Sragovich, S., Schirer, Y., & Idan-Feldman, A. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0701-8 · Cited by 17
“Together with the finding that the ADNP is flanked by diabetes-linked genes (Vulih-Shultzman et al. 2007), the neuropathy/neurodegeneration associated with diabetes and the fact that NAP protected against diabetes-related brain pathologies in the streptozotocin (STZ) injected diabetes rat model…”
BackgroundSelf-citationADNP Regulates Cognition: A Multitasking Protein
Gozes, I. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00873 · Cited by 17
“The direct involvement of ADNP in cognitive function was reported in our 2007 Adnp haploinsufficient mouse model (Vulih-Shultzman et al., 2007) coupled with a paper showing that deletion in the chromosomal area including ADNP [20q12–13.”
BackgroundInfluentialSelf-citationYang, Y., & Xu, L. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-4272-5_13 · Cited by 15
Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats
Zhang, J., Wei, S.-Y., Yuan, L., Kong, L., Zhang, S., Wang, Z., Wu, M., & Qi, J. (2017) · Physiology & Behavior · doi:10.1016/j.physbeh.2017.02.038 · Cited by 15
Kapitansky, O., & Gozes, I. (2019) · GeroScience · doi:10.1007/s11357-019-00079-x · Cited by 15
Self-citationMicrotubule-Tau Interaction as a Therapeutic Target for Alzheimer’s Disease
Ivashko‐Pachima, Y., Zhou, L.-Y., Lei, P., & Gozes, I. (2016) · Journal of Molecular Neuroscience · doi:10.1007/s12031-016-0715-x · Cited by 15
Self-citationKapitansky, O., Giladi, E., Jaljuli, I., Bereswill, S., Heimesaat, M. M., & Gozes, I. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02155-5 · Cited by 15
Self-citationMicrotubule stabilising peptides rescue tau phenotypes in-vivo
Quraishe, S., Sealey, M. A., Cranfield, L., & Mudher, A. K. (2016) · Scientific Reports · doi:10.1038/srep38224 · Cited by 17
Intranasal NAP (Davunetide): Neuroprotection and circadian rhythmicity
Galushkin, A., & Gozes, I. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115573 · Cited by 14
Self-citationExperimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration
Giunta, M., Solje, E., Gardoni, F., Borroni, B., & Benussi, A. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s262352 · Cited by 15
NAP protects against cyanide-related microtubule destruction
Zemlyak, I., Sapolsky, R. M., & Gozes, I. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0252-7 · Cited by 14
“…reduces pathological tau hyperphosphorylation, which is associated with cognitive impairment in tauopathy-related neurodegenerative diseases (Braak and Braak 1991; Gozes and Divinski 2004; Josephs 2008; Matsuoka et al. 2007; Matsuoka et al. 2008; Shiryaev et al. 2009; Vulih-Shultzman et al. 2007).”
BackgroundSelf-citationChu, Y., Morfini, G. A., & Kordower, J. H. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-160812 · Cited by 14
“Additional studies demonstrate that NAP treatment significantly protects cognitive functions and decreases tau hyperphosphorylation in the triple transgenic mouse model of Alzheimer’s disease [8] and in the mutated tau mouse model of frontotemporal dementia [19].”
BackgroundADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment
Malishkevich, A., Leyk, J., Goldbaum, O., Richter‐Landsberg, C., & Gozes, I. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-015-0640-4 · Cited by 13
Self-citationA Novel Microtubule-Tau Association Enhancer and Neuroprotective Drug Candidate: Ac-SKIP
Ivashko‐Pachima, Y., & Gozes, I. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00435 · Cited by 14
Self-citationArya, A., Meena, R., Sethy, N. K., Das, M., Sharma, M., & Bhargava, K. (2015) · Free Radical Research · doi:10.3109/10715762.2015.1011153 · Cited by 13
Ivashko‐Pachima, Y., & Gozes, I. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01632-6 · Cited by 12
Self-citationTau Diagnostics and Clinical Studies
Gozes, I., Höglinger, G. U., Quinn, J. P., Hooper, N. M., & Höglund, K. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0983-0 · Cited by 12
Self-citationCosgrave, A. S., McKay, J. S., Morris, R., Quinn, J. P., & Thippeswamy, T. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9169-0 · Cited by 12
“The dentate gyrus and the hippocampus are commonly involved in temporal lobe epilepsy that closely resembles the kainic acid-induced seizure model in many respects (Nadler 1981; Cole et al. 2002; Velisek and Moshe 2003; Scantlebury et al. 2007).”
BackgroundGozes, I. (2023) · Cytoskeleton · doi:10.1002/cm.21776 · Cited by 11
“Finally, originally we saw ADNP transcriptional regulation of apo-lipoprotein E ( ApoE ) (Mandel et al., 2007), accentuated in female mice (Malishkevich et al., 2015).”
BackgroundInfluentialSelf-citationWang, D., Chernov, A. V., Lam, R., Wang, H., Li, W., Li, X., Duong, T., Wang, S., & Head, B. P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02258-z · Cited by 11
“Interestingly, research from other labs showed that ADNP protects glutamatergic synapses 37 and stabilizes microtubules via tau-microtubule binding, 38 – 40 consistent with pathways identi fi ed by the transcriptome.”
Moreau, M., Carmona‐Iragui, M., Altuna, M., Dalzon, L., Barroeta, I., Vilaire-Meunier, M., Durand, S., Fortea, J., Rebillat, A., & Janel, N. (2022) · Biomedicines · doi:10.3390/biomedicines10061380 · Cited by 12
“ADNP-haploinsufficient mice exhibit age-related tauopathy, neurodegeneration, and cognitive deficits [39].”
BackgroundHacohen-Kleiman, G., Barnea, A., & Gozes, I. (2015) · Peptides · doi:10.1016/j.peptides.2015.04.008 · Cited by 12
Self-citationSpecific protein biomarker patterns for Alzheimer’s disease: improved diagnostics in progress
Gozes, I. (2017) · The EPMA Journal · doi:10.1007/s13167-017-0110-x · Cited by 11
“for brain formation [21], and ADNP deficits in mice results in tau pathology coupled to cognitive impairments [22].”
BackgroundSelf-citationActivity-Dependent Neuroprotective Protein (ADNP): An Overview of Its Role in the Eye
Maugeri, G., D’Amico, A. G., Magrì, B., Musumeci, G., & D’Agata, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113654 · Cited by 10
“For example, hyperphosphorylated tau deposits associated with visually evoked potential impairments were found in the hippocampus of ∼2-month-old Tyr-Adnp with respect to 11-month-old Adnp+/− male mouse brains [48].”
BackgroundInfluentialHacohen-Kleiman, G., Moaraf, S., Kapitansky, O., & Gozes, I. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01700-x · Cited by 10
Self-citationJain, K. K. (2011) · Humana Press eBooks · doi:10.1007/978-1-61779-049-2_2 · Cited by 10
Tracing the invisible mutant ADNP protein in Helsmoortel-Van der Aa syndrome patients
D’Incal, C. P., Cappuyns, E., Choukri, K., Man, K. D., Szrama, K., Konings, A., Bastini, L., Meel, K. V., Buys, A., Gabriele, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-65608-x · Cited by 9
“A significant reduction of ADNP was observed in Adnp haploinsufficient mice, although the molecular weight was not mentioned 20 .”
BackgroundExtended phenotypic characterization of a novel Helsmoortel‐van der Aa syndrome case series
Pascolini, G., Zenzo, G. D., Panebianco, A., Didona, B., & Gozes, I. (2024) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63539 · Cited by 8
“Thus, Helsmoortel-van der Aa syndrome with ADNP linked to SWI/SNF or BAF chromatin remodeling complex (Mandel & Gozes, 2007) manifests a skin involvement, like other chromatin disorders, including Koolen-de Vries (KDVS, MIM#610443) and BAF complex-related syndromes (Khazanchi et al., 2019; Koolen…”
BackgroundSelf-citationGozes, I., Shazman, S., Giladi, E., & Levine, J. (2024) · Genomic psychiatry : · doi:10.61373/gp024r.0079 · Cited by 8
“Over the last years, we have established cellular (6, 11– 14) and animal models (4, 15, 16) to characterize ADNP function and the potential protection by the ADNP-derived investigational drug, davune-tide (also known as NAP, AL-108, CP201).”
Self-citationSragovich, S., Amram, N., Yeheskel, A., & Gozes, I. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00589 · Cited by 8
Self-citationModerate Physical Activity Increases the Expression of ADNP in Rat Brain
Maugeri, G., D’Amico, A. G., Federico, C., Saccone, S., D’Agata, V., & Musumeci, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084382 · Cited by 7
Wang, Y., Sun, X., Xiong, B., Duan, M., & Sun, Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179469 · Cited by 7
Ivashko‐Pachima, Y., Seroogy, K. B., Sharabi, Y., & Gozes, I. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01876-w · Cited by 7
“NAP treatment corrects these abnormalities (Vulih-Shultzman et al. 2007; Hacohen-Kleiman et al. 2018; Sragovich et al. 2019).”
BackgroundSelf-citationGozes, I. (2010) · The EPMA Journal · doi:10.1007/s13167-010-0029-y · Cited by 7
“To understand the biological significance of NAP (davunetide) activity, we have generated mice partially deficient of the NAP (davunetide) -containing protein, ADNP [100].”
BackgroundResultInfluentialSelf-citationNeuroprotective Drug Development: The Story of ADNP, NAP (Davunetide), and SKIP
Gozes, I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00013-2 · Cited by 7
Self-citationUse of biomarkers in the diagnosis of Alzheimer’s disease in adults with intellectual disability
McFeely, A., O’Connor, A., & Kennelly, S. (2024) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2024.100639 · Cited by 6
Peptides NAP and SAL attenuate human tau granular-shaped oligomers in vitro and in SH-SY5Y cells
Mokhtari, F., Riazi, G. H., Balalaie, S., Khodarahmi, R., Karima, S., Hemati, A., Bolouri, B., Katouli, F. H., & Fathi, E. (2016) · Neuropeptides · doi:10.1016/j.npep.2016.06.005 · Cited by 7
“Reduction of tau phosphorylation and functional compensation of abnormal tau in tauopathy models are well defined by NAP (Divinski et al., 2006; Quraishe et al., 2013; Vulih-Shultzman et al., 2007).”
BackgroundUtilizing an Animal Model to Identify Brain Neurodegeneration-Related Biomarkers in Aging
Yang, M., Chen, Y. A., Tu, S.-C., Chi, P., Chuang, K., Chang, C.-C., Lee, C.-H., Chen, Y., Lee, C., Yuan, C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063278 · Cited by 6
“It is also shown that ADNP is an essential protein for brain function, and plays an important role in the ability to have normal cognitive function [24,25].”
BackgroundEpisignatures stratifying ADNP syndrome show modest correlation with phenotypePreprint
Breen, M. S., Garg, P., Tang, L., Mendonca, D., Levy, T., Barbosa, M., Arnett, A. B., Kurtz‐Nelson, E. C., Agolini, E., Battaglia, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.01.014902 · Cited by 6
Gozes, I., Blatt, J., & Guz, L. S. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03675-y · Cited by 5
Self-citationSex-Specific ADNP/NAP (Davunetide) Regulation of Cocaine-Induced Plasticity
Toren, Y., Ziv, Y., Sragovich, S., McKinney, R. A., Barak, S., Shazman, S., & Gozes, I. (2024) · Journal of Molecular Neuroscience · doi:10.1007/s12031-024-02234-2 · Cited by 5
“…sex-dependent deficiencies in ADNP-mutated mice (Gozes 2017), coupled with sex-dependent effects on dendritic spines, axonal transport, and tubulin isotype expression (Amram et al. 2016; Hacohen-Kleiman et al. 2018; Karmon et al. 2022; Sragovich et al. 2019a, b; Vulih-Shultzman et al. 2007).”
BackgroundSelf-citationMicrotubule stabilising peptides: new paradigm towards management of neuronal disorders
Bhargava, S., Kulkarni, R., Dewangan, B., Kulkarni, N., Jiaswar, C., Kumar, K., Kumar, A., Bodhe, P. R., Kumar, H., & Sahu, B. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00012e · Cited by 5
Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States
Aso, E., & Ferrer, I. (2013) · InTech eBooks · doi:10.5772/54783 · Cited by 5
“Finally, the peptide NAP stabilizes microtubules and reduces tau hyper-phosphorylation [92].”
Wauters, E., Sleegers, K., Cruts, M., & Broeckhoven, C. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00009-9 · Cited by 6
Emerging Therapeutic Strategies in Alzheimer's Disease
Chiba, T. (2013) · InTech eBooks · doi:10.5772/55293 · Cited by 5
“NAP suppressed zinc-mediated microtubule depolyme‐ rization in astrocytes by promoting microtubule assembly and reorganization (Gozes and Divinski, 2007; Vulih-Shultzman et al., 2007).”
BackgroundTargeted tau protein degradation: a promising therapeutic approach for tauopathies
Baazaoui, N., Alfaifi, M. Y., Shati, A. A., Saad, R. B., & Garzoli, S. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.11.041 · Cited by 5
Berg, E. L., & Silverman, J. L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-816393-1.00010-5 · Cited by 4
How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
Lozupone, M., Dibello, V., Daniele, A., Solfrizzi, V., Resta, E., & Panza, F. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2345734 · Cited by 5
“Davunetide, an oligopeptide deriving from the activity-dependent neuroprotective peptide (ADNP), decreased tau phosphorylation in ADNP± transgenic mice [28], stabilizing microtubules in neurons through inhibition of apoptosis and correcting mitochondrial dysfunction [28].”
BackgroundGalushkin, A., & Gozes, I. (2024) · Current Research in Biotechnology · doi:10.1016/j.crbiot.2024.100254 · Cited by 4
Self-citationPejman, S., Riazi, G., Pooyan, S., & Lanjanian, H. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00552 · Cited by 4
D’Incal, C. P., Cappuyns, E., Choukri, K., Szrama, K., Man, K. D., der Aa, N. V., Dijck, A. V., Kooy, R. F., & Berghe, W. V. (2022) · Research Square · doi:10.21203/rs.3.rs-1954095/v1 · Cited by 4
Verma, P., Khatun, R., Jew, K. A., Prusty, S. K., & Knafo, S. (2025) · Neuropeptides · doi:10.1016/j.npep.2025.102559 · Cited by 3
Saleh, A. Y., Saputra, D. A. Y., Valentina, R., & Susanto, T. D. (2025) · F1000Research · doi:10.12688/f1000research.160416.3 · Cited by 1
Disentangling the role of tau pathology in autism spectrum disorders
Villavicencio-Tejo, F., Olesen, M. A., Moya, M. L., & Quintanilla, R. A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111496 · Cited by 4
The ADNP-Mediated Transcriptome Response to Ketamine Impairs the Cytoskeletal Protein Axis
D’Incal, C. P., Mateiu, L. M., Man, K. D., Elinck, E., Gozes, I., & Kooy, R. F. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02420-w · Cited by 3
“For instance, homozygous deletion of Adnp in mice results in embryonic lethality and failure of neural tube closure (Pinhasov et al. 2003), whereas heterozygous mice are viable (Vulih-Shultzman et al. 2007; Karmon et al. 2022; D’Incal et al. 2025; Cho et al. 2023).”
InfluentialSelf-citationNatural Plant Materials as a Source of Neuroprotective Peptides
Skibska, A., & Perlikowska, R. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230703145043 · Cited by 3
Gozes, I. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00134 · Cited by 3
“Furthermore, partial ADNP deficiency leads to cognitive and social dysfunction (Vulih-Shultzman et al., 2007), similar to partial deficiency in VIP functions (Glowa et al., 1992; Gozes et al., 1993; Hill et al., 2007).”
BackgroundSelf-citationGozes, I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00001-x · Cited by 3
Self-citationD’Incal, C. P., Cappuyns, E., Paldi, F., van der Lei, M. B., Annear, D. J., Alastruey, C. M., Sokolova, D., Elinck, E., Man, K. D., Konings, A., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106309 · Cited by 4
“12 Mice lacking all Adnp exons ( Δ exons 1–6) demonstrated cognitive deficits in the MWM test, 25 consistent with those reported in a neuron-specific Adnp knock-down model.”
Potential Therapeutic Strategies for Neurodegenerative Diseases
Farooqui, A. A. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6652-0_9 · Cited by 2
PACAP, VIP, and ADNP: Autism and Schizophrenia
Gozes, I. (2016) · Current topics in neurotoxicity · doi:10.1007/978-3-319-35135-3_46 · Cited by 2
Self-citationD’Incal, C. P., Dijck, A. V., Annear, D. J., Harutyunyan, L., Elinck, E., Dingemans, A. J. M., Vries, B. B. A. D., Mateiu, L. M., Meuwissen, M. E. C., Jansen, A., et al. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01998-7 · Cited by 2
“Ultimately, indications for neurode-generation have been observed in cellular and murine models for the Helsmoortel-Van der Aa syndrome [13, 20, 42, 43].”
VIP–PACAP 2010: My Own Perspective on Modulation of Cognitive and Emotional Behavior
Gozes, I. (2010) · Journal of Molecular Neuroscience · doi:10.1007/s12031-010-9456-4 · Cited by 2
“We then demonstrated that partial ADNP deficiency (ADNP+/–) resulted in cognitive and social impairments that were coupled to tauopathy, a major pathology in Alzheimer’s disease and frontotemporal dementia ( Vulih-Shultzman et al. 2007 ).”
BackgroundMethodSelf-citationNovel therapeutics based on tau/microtubule dynamics: WO2008084483
Alonso, A. D. C., & Corbo, C. P. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902887815 · Cited by 2
“Gozes and collaborators had tried the NAP peptide on recovering nerve injury in rats intraperitoneal and intraocular [14], on preventing cognitive decline in a mouse model of tauopathy [15] or preventing tau phosphorylation in a mouse model ANDP deficient mouse [16].”
MethodChemical Modulators of Protein Misfolding, Neurodegeneration and Tau
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00001-1 · Cited by 2
Activity-Dependent Neuroprotective Protein (ADNP) and Davunetide (NAP)
Gozes, I., & Baas, P. W. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00220-7 · Cited by 2
Self-citationClinical and Genetic Characterization of Patients with ADNP Related Helsmoortel-Van der Aa Syndrome
Kafley, P., Saxena, D., & Moirangthem, A. (2026) · The Indian Journal of Pediatrics · doi:10.1007/s12098-025-05894-z · Cited by 1
Tauopathies and its therapeutic interventions in Alzheimer’s disease
Sonawane, S. K., Rangappa, N., Chidambaram, H., & Chinnathambi, S. (2026) · Advances in pharmacology · doi:10.1016/bs.apha.2025.12.001 · Cited by 1
Galushkin, A., Giladi, E., & Gozes, I. (2026) · Neurobiology of Disease · doi:10.1016/j.nbd.2026.107509 · Cited by 1
Self-citationShapira, G., Blatt, J., Guz, L. S., Shomron, N., & Gozes, I. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03709-x · Cited by 1
“This is consistent with our animal studies modeling ADNP mutations in mice [3, 5, 20, 23], showing increased tauopathy in young male mice, compared to female mice [5, 24], which is ameliorated by davunetide treatment.”
Self-citation
Metadata
- Authors
- Vulih-Shultzman, I., Pinhasov, A., Mandel, S., Grigoriadis, N., Touloumi, O., Pittel, Z., & Gozes, I.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2007-11
- Volume
- 323
- Issue
- 2
- Pages
- 438-449
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2136172091
- Cited by
- 219
- References
- 40
- Citations by year
- 2026: 10 · 2025: 12 · 2024: 12 · 2023: 9 · 2022: 14 · 2021: 9 · 2020: 19 · 2019: 18 · 2018: 7 · 2017: 11 · 2016: 15 · 2015: 13 · 2014: 14 · 2013: 11 · 2012: 13
- FWCI
- 5.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- ADNP, NAP peptide, tau hyperphosphorylation, cognitive impairment, learning, neurodegeneration, tauopathy, Alzheimer's disease, mild cognitive impairment, neuroprotection, microtubule binding
- MeSH terms
- Animals, Astrocytes, Cognition Disorders, Female, Learning, Male, Mice, Inbred ICR, Mice, Transgenic, Nerve Tissue Proteins, Oligopeptides, Phosphorylation, tau Proteins, Homeodomain Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
